4 - Akouos, Inc. (0001722271) (Issuer)

4 - Akouos, Inc. (0001722271) (Issuer)

4 - Akouos, Inc. (0001722271) (Issuer)

4 - Akouos, Inc. (0001722271) (Issuer)

4 - Akouos, Inc. (0001722271) (Issuer)

4 - Akouos, Inc. (0001722271) (Issuer)

4 - Akouos, Inc. (0001722271) (Issuer)

4 - Akouos, Inc. (0001722271) (Issuer)

4 - Akouos, Inc. (0001722271) (Issuer)

4 - Akouos, Inc. (0001722271) (Issuer)

BOSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer. Dr. Tward is a surgeon and a scientist with deep experience in genetics, genomics, gene delivery, high-throughput sequencing technologies, and the clinical care of patients with conditions of the ear and skull base. Dr. Tward was previously a member of the Akouos scientific advisory board since 2018. As chief scientific officer, he will lead the research team, and provide strategic scie

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Stacy Price as chief technical officer. Ms. Price brings to Akouos more than 25 years of experience managing clinical and commercial biotechnology manufacturing and technical operations for a wide range of therapeutic modalities, including gene therapy. At Akouos, she will be responsible for the strategy and operations of vector development and manufacturing, as well as device development and engineering. "We are excited to welcome Stacy to

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Dr. Kathy Reape as chief development officer. Dr. Reape brings over 20 years of experience in the pharmaceutical industry, including significant gene therapy translational and development expertise, to Akouos. "We welcome Dr. Reape to the Akouos team at this exciting time in the company's growth, as we continue to advance the AK-OTOF and AK-antiVEGF programs towards our planned IND submissions in 2022," said Manny Simons, Ph.D., M.B.A., co-f

INDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ:AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. "Akouos brings more top-tier talent and an important pipeline to Lilly's Institute for Genetic Medicine that will further accelerate our work to advance genetic medicines for people living with difficult-to-treat diseases," said Andrew C. Adams, Ph.D., senior vice president of genetic medicine

INDIANAPOLIS and BOSTON, Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Akouos, Inc. (NASDAQ:AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones (the "Offer"), expire

-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2022 and provides business highlights. "This has been a transformative year for us, and we've achieved

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Ritchie Bros. Auctioneers Incorporated (NYSE:RBA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of IAA, Inc. to RBA for $10.00 per share in cash and 0.5804 shares of RBA common stock for each share of IAA common stock. If you are an RBA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected]. Akouos, Inc. (NASDAQ:AKUS) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connect

Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide Transaction valued at approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million INDIANAPOLIS and BOSTON, Oct. 18, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Akouos, Inc. (NASDAQ:AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. "We are hon

SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, which has an additional mandate to invest in public market opportunities. 5AM is pleased to announce the addition of two Venture Partners to the firm's investment team, and a Venture Advisor to the advisory team. Dr. Arthur Tzianabos has joined 5AM as a Venture Pa

-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the first for an AAV vector therapy with the potential to treat an inner ear condition -Akouos plans to initiate a pediatric Phase 1/2 clinical trial, including children as young as two years of age in the dose-escalation phase (Part A), to evaluate AK-OTOF for the treatment of OTOF-mediated hearing loss -Based on auditory brainstem response data from nonclinical studies, a one-time administration of AK-OTOF has the potential to deliver durable restoration of auditory function BOSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicat

Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expression in the inner ear Received a notice of allowance from USPTO for claims covering compositions, including AK-OTOF, and methods of treatment useful for OTOF-mediated hearing lossEnded Q2 2022 with a strong cash position of $192.9 million BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing los

- Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical development of AK-OTOF for the treatment of OTOF-mediated hearing loss - MicroRNA target site (miR-TS)-incorporation in AAV vectors is shown to have potential benefits for de-targeting transgene expression in the inner ear, supporting future development of gene therapies targeting a broad range of inner ear conditions BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living wi

- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at ASGCT supporting the planned clinical development of AK-OTOF and highlighting the potential use of microRNA target sites in AAV vectors for regulated gene expression in the inner ear - Presented new nonclinical data at ARO demonstrating potential of precision genetic medicine platform to address a broad range of inner ear conditions -Ended the first quarter with a strong cash position of $209.1 million BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potenti

15-12G - Akouos, Inc. (0001722271) (Filer)

EFFECT - Akouos, Inc. (0001722271) (Filer)

POS AM - Akouos, Inc. (0001722271) (Filer)

S-8 POS - Akouos, Inc. (0001722271) (Filer)

S-8 POS - Akouos, Inc. (0001722271) (Filer)

S-8 POS - Akouos, Inc. (0001722271) (Filer)

8-K - Akouos, Inc. (0001722271) (Filer)

25-NSE - Akouos, Inc. (0001722271) (Subject)

SC 14D9/A - Akouos, Inc. (0001722271) (Subject)

SC TO-T/A - Akouos, Inc. (0001722271) (Subject)

William Blair initiated coverage of Akouos with a rating of Outperform and set a new price target of $12.00

HC Wainwright & Co. initiated coverage of Akouos with a rating of Buy and set a new price target of $25.00

BofA Securities downgraded Akouos from Buy to Neutral and set a new price target of $20.00 from $24.00 previously

-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2022 and provides business highlights. "This has been a transformative year for us, and we've achieved

Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expression in the inner ear Received a notice of allowance from USPTO for claims covering compositions, including AK-OTOF, and methods of treatment useful for OTOF-mediated hearing lossEnded Q2 2022 with a strong cash position of $192.9 million BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing los

- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at ASGCT supporting the planned clinical development of AK-OTOF and highlighting the potential use of microRNA target sites in AAV vectors for regulated gene expression in the inner ear - Presented new nonclinical data at ARO demonstrating potential of precision genetic medicine platform to address a broad range of inner ear conditions -Ended the first quarter with a strong cash position of $209.1 million BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potenti

- Advanced toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presented data at ARO demonstrating potential of precision genetic medicine platform to address a broad range of inner ear conditions - Expanded leadership team with appointment of otology leader Aaron Tward, M.D., Ph.D., as chief scientific officer - Ended 2021 with a strong cash position of $232.5 million BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the fourth quarter and f

- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Expanded leadership team with appointment of Stacy Price as chief technical officer BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2021, and provides business highlights. "This quarter we advanced our lead programs, AK-OTOF and AK-antiVEGF, toward planned 2022 IND submissions, and we continue to apply our genetic medicines platform

- Announced European Commission designation of AK-OTOF as an orphan drug for the treatment of otoferlin gene-mediated hearing loss - Advanced both AK-OTOF and AK-antiVEGF towards planned IND submissions in the first half of 2022 and in 2022, respectively - Continued to broaden application of genetic medicines platform to treat additional inner ear conditions BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the second quarter ended June 30, 2021 and provides business highlights. "Duri

SC 13G/A - Akouos, Inc. (0001722271) (Subject)

SC 13G/A - Akouos, Inc. (0001722271) (Subject)

SC 13G/A - Akouos, Inc. (0001722271) (Subject)

SC 13G/A - Akouos, Inc. (0001722271) (Subject)

SC 13D/A - Akouos, Inc. (0001722271) (Subject)

SC 13D/A - Akouos, Inc. (0001722271) (Subject)

SC 13D/A - Akouos, Inc. (0001722271) (Subject)

SC 13G - Akouos, Inc. (0001722271) (Subject)

SC 13D - Akouos, Inc. (0001722271) (Subject)

SC 13G/A - Akouos, Inc. (0001722271) (Subject)

Although US stocks closed mixed on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Live Nation Entertainment The Trade: Live Nation Entertainment, Inc. (NYSE:LYV) Director Jimmy Iovine acquired a total of 13,74

Akouos (NASDAQ:AKUS) reported quarterly losses of $(0.54) per share. This is a 19.4 percent increase over losses of $(0.67) per share from the same period last year.

Upgrades According to Raymond James, the prior rating for Fortis Inc (NYSE:FTS) was changed from Market Perform to Outperform. In the second quarter, Fortis showed an EPS of $0.45, compared to $0.45 from the year-ago quarter. The stock has a 52-week-high of $51.66 and a 52-week-low of $34.76. At the end of the last trading period, Fortis closed at $37.76. According to UBS, the prior rating for BanColombia SA (NYSE:CIB) was changed from Sell to Neutral. For the second quarter, BanColombia had an EPS of $1.78, compared to year-ago quarter EPS of $1.28. The current stock performance of BanColombia shows a 52-week-high of $45.98 and a 52-week-low of $23.97. Moreover, at the end of the last tra

Piper Sandler analyst Yasmeen Rahimi downgrades Akouos (NASDAQ:AKUS) from Overweight to Neutral and lowers the price target from $18 to $13.

William Blair analyst Sami Corwin downgrades Akouos (NASDAQ:AKUS) from Outperform to Market Perform.

Gainers COMSovereign Holding Corp. (NASDAQ:COMS) shares jumped 170.1% to close at $0.1194 on Tuesday after gaining 4% on Monday. Akouos, Inc. (NASDAQ:AKUS) shares surged 88.2% to close at $13.19 on Tuesday. Eli Lilly And Co (NYSE:LLY) agreed to acquire Akouos for a 78% premium over Monday’s closing price of $7.01. Rubicon Technologies, Inc. (NYSE:RBT) climbed 58.2% to close at $1.74. Helbiz, Inc. (NASDAQ:HLBZ) climbed 58.1% to close at $0.4211. Helbiz CEO Salvatore Palella recently acquired a total of 200,000 shares at an average price of $0.25. Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) jumped 44.4% to close at $2.73 after the company announced plans to initiate a second clinical tri

U.S. stocks closed higher on Monday, with the Dow Jones gaining more than 300 points. Here is the list of some big stocks recording gains in the previous session. Akouos, Inc. (NASDAQ:AKUS) shares surged 88.2% to close at $13.19 on Tuesday. Eli Lilly And Co (NYSE:LLY) agreed to acquire Akouos for a 78% premium over Monday’s closing price of $7.01. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) gained 42.4% to close at $14.92 after LG Chem announced it will acquire AVEO Oncology for $15 per share in cash. Novonix Limited (NASDAQ:NVX) rose 20.4% to close at $5.61. IAMGOLD Corporation (NYSE:IAG) rose 19.8% to close at $1.27 after the company announced an agreement to sell its interest in Rose

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 300 points on Tuesday. The Dow traded up 1.02% to 30,492.91 while the NASDAQ rose 0.57% to 10,736.71. The S&P 500 also rose, gaining, 0.94% to 3,712.55. Also check this: Fear & Greed Index Moves To 'Fear' Zone After Dow Jumps 550 points Leading and Lagging Sectors Industrials shares climbed 2.1% on Tuesday. Leading the sector was strength from KULR Technology Group, Inc. (NYSE:KULR) and ADS-TEC Energy PLC (NASDAQ:ADSE). In trading on Tuesday, health care shares rose by just 0.4%. Top Headline   The Goldman Sachs Group, Inc. (NYSE:GS) reported better-than-expected Q3 results. Goldman Sachs G

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Tuesday. The Dow traded up 1.07% to 30,508.96 while the NASDAQ rose 1.12% to 10,795.82. The S&P 500 also rose, gaining, 1.17% to 3,721.03. Also check this: Fear & Greed Index Moves To 'Fear' Zone After Dow Jumps 550 points Leading and Lagging Sectors Industrials shares climbed 2.1% on Tuesday. Leading the sector was strength from KULR Technology Group, Inc. (NYSE:KULR) and Lockheed Martin Corporation (NYSE:LMT). In trading on Tuesday, energy shares rose by just 0.3%. Top Headline   The Goldman Sachs Group, Inc. (NYSE:GS) reported better-than-expected Q3 results. Goldman Sach

https://techydailynews.com/2022/10/18/decibel-therapeutics-hears-it-may-be-a-takeout-target-after-lilly-acquisition-of-akouos/ Therapeutic Decibel (NASDAQ:DBTX), which focuses on treatments for hearing loss, is up to 25% in the Tuesday morning exchanges after Eli Lilly (NYSE:LLY) announced that it would acquire hearing therapy company Akouos (NASDAQ:AKUS). One of Decibel (DBTX) the most anticipated program is DB-OTO, a gene therapy designed to restore hearing in people born with significant hearing loss due to a mutation in the OTOF gene. On Monday, the US FDA authorized an IND request to start a phase 1/2 trial. The candidate is the first developed in a collaboration with Regeneron Pharm